United Therapeutics Corporation Earnings

The next earnings date for United Therapeutics Corporation is July 28, 2026.

They are scheduled to announce earnings before the market opens that day.

Analyst Estimates of United Therapeutics Corporation Earnings

Report Date	Estimated Earnings Per Share
07/28/2026	$7.26

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

United Therapeutics Corporation Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
05/06/2026	Before Market	$5.82	-16.92%
02/25/2026	Before Market	$7.70	5.05%
10/29/2025	Before Market	$7.16	-2.35%
07/30/2025	Before Market	$6.41	-9.46%
04/30/2025	Before Market	$6.63	-0.45%
02/26/2025	Before Market	$6.19	-3.83%
10/30/2024	Before Market	$6.39	-2.49%
07/31/2024	Before Market	$5.85	-10.35%
05/01/2024	Before Market	$6.17	7.04%
02/21/2024	Before Market	$4.36	2.12%
11/01/2023	Before Market	$5.38	4.59%
08/02/2023	Before Market	$5.24	14.02%
05/03/2023	Before Market	$4.86	5.31%
02/22/2023	Before Market	$2.67	-41.99%
11/02/2022	Before Market	$4.91	23.61%
08/03/2022	Before Market	$2.41	-42.84%
05/04/2022	Before Market	$5.03	47.41%
02/24/2022	Before Market	$2.35	-38.00%
11/03/2021	Before Market	$3.42	-6.66%
08/04/2021	Before Market	$3.65	18.49%
05/05/2021	Before Market	$0.61	-79.67%
02/24/2021	Before Market	$2.19	-31.59%
10/28/2020	Before Market	$3.86	33.67%
07/29/2020	Before Market	$2.41	-17.70%
04/29/2020	Before Market	$3.12	11.23%
02/26/2020	Before Market	$1.20	-56.12%
10/30/2019	Before Market	$3.16	26.97%
07/31/2019	Before Market	$4.11	61.68%
05/01/2019	Before Market	$2.81	-0.79%
02/27/2019	Before Market	$1.48	-43.02%
10/31/2018	Before Market	$2.42	-27.10%
08/01/2018	Before Market	$3.98	23.09%
05/02/2018	Before Market	$5.57	55.41%
02/21/2018	Before Market	$3.89	-2.04%
10/25/2017	Before Market	$6.27	58.81%
07/27/2017	Before Market	$4.40	19.41%
04/26/2017	Before Market	$3.89	15.34%
02/22/2017	Before Market	$2.49	-32.46%
10/27/2016	Before Market	$3.50	2.89%
07/28/2016	Before Market	$4.39	33.81%
04/28/2016	Before Market	$4.84	47.87%
02/25/2016	Before Market	$2.10	-19.39%
10/27/2015	Before Market	$4.91	89.59%
07/28/2015	Before Market	$1.91	-19.00%
04/28/2015	Before Market	$-0.36	-116.50%
02/24/2015	Before Market	$2.37	14.62%
10/28/2014	Before Market	$-0.53	-126.33%
07/29/2014	Before Market	$2.10	17.37%
04/29/2014	Before Market	$2.43	44.60%
02/25/2014	Before Market	$-0.60	-138.94%
10/29/2013	Before Market	$1.17	-27.93%
07/25/2013	Before Market	$1.52	1.48%
04/25/2013	Before Market	$1.19	-20.81%
02/26/2013	Before Market	$1.60	25.99%
11/01/2012	Before Market	$1.04	-18.93%
07/26/2012	Before Market	$1.34	17.54%
04/26/2012	Before Market	$1.29	36.21%
02/14/2012	Before Market	$0.77	-13.41%
10/27/2011	Before Market	$1.32	78.23%
07/28/2011	Before Market	$1.18	120.11%
04/28/2011	Before Market	$0.33	-49.45%
02/15/2011	Before Market	$0.15	-76.44%
10/28/2010	Before Market	$0.66	20.95%
07/28/2010	Before Market	$0.62	36.41%
04/29/2010	Before Market	$0.32	7.93%
02/16/2010	Before Market	$-0.06	-121.11%
10/29/2009	Before Market	$0.21	-30.97%
07/31/2009	Before Market	$-0.05	-116.04%
05/01/2009	Before Market	$0.25	-21.63%
02/17/2009	Before Market	$-1.71	-737.11%
10/30/2008	Before Market	$0.25	-15.02%
07/31/2008	Before Market	$0.29	0.41%
05/01/2008	Before Market	$0.23	-13.79%
02/19/2008	Before Market	$0.04	-82.53%
11/01/2007	Before Market	$0.33	91.19%
07/31/2007	Before Market	$0.13	-29.35%
05/01/2007	Before Market	$0.22	-27.58%
02/20/2007	Before Market	$0.38	5.78%
10/31/2006	Before Market	$0.37	37.91%
08/01/2006	Before Market	$0.34	68.07%
05/02/2006	Before Market	$0.19	-19.15%
02/21/2006	Before Market	$0.57	69.34%
10/31/2005	Before Market	$0.31	23.18%
08/02/2005	Before Market	$0.25	46.18%
05/03/2005	Before Market	$0.16	7.94%
02/22/2005	Before Market	$0.14	31.58%
11/03/2004	Before Market	$0.14	61.10%
08/03/2004	Before Market	$0.09	4,600.00%
05/06/2004	Before Market	$-0.05	-278.15%
02/24/2004	Before Market	$-0.08	-102.70%
11/06/2003	Before Market	$-0.03	30.88%
08/05/2003	Before Market	$-0.05	-15.55%
05/06/2003	Before Market	$-0.07	27.76%
02/25/2003	After Market	$-0.06	30.80%
11/08/2002	After Market	$-0.14	11.15%
08/10/2001	Before Market	$-0.26	-8.25%
05/09/2001	Before Market	$-0.23	1.96%
03/21/2001	Before Market	$-0.29	-12.23%
11/02/2000	Before Market	$-0.17	35.66%
08/09/2000	Before Market	$-0.25	-0.78%
05/09/2000	Before Market	$-0.22	8.22%
03/02/2000	Before Market	$-0.28	4.28%
11/08/1999	After Market	$-0.20	23.61%
08/06/1999	Before Market	$-0.26	15.52%

More About United Therapeutics Corporation

Website

https://www.unither.com

Country

USA

Full Time Employees

1,400

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

“United Therapeutics Corporation Earnings” Can Refer to the United Therapeutics Corporation Earnings Date

Some people say “United Therapeutics Corporation earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my United Therapeutics Corporation position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning United Therapeutics Corporation Stock on the Earnings Date

If you own United Therapeutics Corporation stock (UTHR) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for United Therapeutics Corporation might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading United Therapeutics Corporation shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More United Therapeutics Corporation Earnings

You can contact us any time if you would like to ask questions about United Therapeutics Corporation earnings or anything else related to the stock market.